Phase 4
Completed N=72
Empagliflozin and Hepatic Glucose Metabolism
Hepatic Glucose Metabolism
Source: ClinicalTrials.gov NCT03193684 ↗
Enrolled (actual)
72
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: Effect of Empagliflozin on Autonomic Nervous System — 480; 621; 355; 635 ng/min
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effect of Empagliflozin on Autonomic Nervous System |
480; 621; 355; 635 | — |
| SECONDARY Hepatic Glucose Production |
2.57; 2.63; 3.15; 2.50 | — |
Eligibility Criteria
Inclusion Criteria
- eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy
Exclusion Criteria
- eGFR <60 T2DM patients on insulin, GLP-1 RA or SGLT2 treatment Major organ disease type 1 diabetes
Data sourced from ClinicalTrials.gov (NCT03193684). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.